Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Maartje W RohaanTroels H BorchJoost H van den BergÖzcan MetRob KesselsMarnix H Geukes FoppenJoachim Stoltenborg GranhøjBastiaan NuijenCynthia NijenhuisInge JedemaMaaike van ZonSaskia ScheijJos H BeijnenMarten HansenCarlijn VoermansInge M NoringriisTine J MonbergRikke B HolmstroemLidwina D V WeverMarloes van DijkLindsay G Grijpink-OngeringLudy H M ValkenetAlejandro Torres AcostaMatthias KargerJessica S W BorgersRenske M T Ten HamValesca P RetèlWim H van HartenFerry LalezariHarm van TinterenAstrid A M van der VeldtGeke A P HospersMarion A M Stevense-den BoerKarijn P M SuijkerbuijkMaureen J B AartsDjura PiersmaAlfons J M van den EertweghJan-Willem B de GrootGerard VreugdenhilEllen KapiteijnMarye J Boers-SonderenW Edward FietsFranchette W P J van den BerkmortelEva EllebaekLisbet R HölmichAlexander C J van AkkooiWinan J van HoudtMichel W J M WoutersJohannes V van ThienenChristian U BlankAafke Meerveld-EgginkSebastian KlobuchSofie WilgenhofTon N SchumacherMarco DoniaInge Marie SvaneJohn B A G HaanenPublished in: The New England journal of medicine (2023)
In patients with advanced melanoma, progression-free survival was significantly longer among those who received TIL therapy than among those who received ipilimumab. (Funded by the Dutch Cancer Society and others; ClinicalTrials.gov number, NCT02278887.).